New women’s health biotech KaNDy Therapeutics—rumored to have attracted buyout interest from Allergan—has just reported data on its lead product that could enhance its allure.

This content was originally published here.

Curt Warner - Editor NMA
Submitted by: Curt Warner - Editor NMA